American Society of Hirudotherapy

Piguamerin

Plasma kallikrein and trypsin inhibitor from Korean leech — anti-inflammatory and antithrombotic research.

Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Piguamerin compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaPiguamerin5.9 kDa
Molecular weight (kilodaltons) of Piguamerin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Plasma kallikrein and trypsin inhibitor from Korean leech — anti-inflammatory and antithrombotic research.
Evidence level
In vitro
Drug vs leech
Purified natural compound

Clinical translation limit

Piguamerin's in vitro inhibition of plasma kallikrein and trypsin does not establish clinical efficacy. No FDA-approved derivative exists. Mechanism is preclinical/biochemical only.

Molecular Profile

Category
Proteinase Inhibitor
Evidence tier
Preclinical
Molecular weight
5,860 Da
Source species
Hirudo nipponia
Discovered
1998 · Kim DR et al.
Piguamerin molecular structure

Biological Targets

  • plasma kallikrein
  • trypsin

Key Citations

  1. Kim DR, Kang KW (1998), Eur J Biochem · PMID 9688284

External Resources

    Related Proteinase Inhibitor Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.